Arca
Skip to content

Innovision-Dxii

System, X-Ray, Stationary. 510(k) K250790, from Dk Medical Systems Co., Ltd. (Pyeongtaek-Si, KR). Product code KPR, class 2.

As of Nov 17, 2026, K250790 is an FDA 510(k) held by Dk Medical Systems Co., Ltd., substantially equivalent on Aug 1, 2025 after 140 days, with no recalls tied to it in FDA's recall database.

  • Substantially equivalent: Aug 1, 2025
  • Review time: 140 days
  • Recalls: 0

Indications for Use

As the 510(k) summary states them, read from FDA's summary PDF

INNOVISION-DXII is a stationery X-ray system intended for obtaining radiographic images of various anatomical parts of the human body, both pediatrics and adults, in a clinical environment. INNOVISION-DXII is not intended for mammography, angiography, interventional, or fluoroscopy use.

Predicate Devices

The legally marketed devices this 510(k) summary says it is substantially equivalent to, read from FDA's summary PDF

Other KPR Clearances

The newest 510(k)s for the same product code; their median review was 195 days; see every KPR device

Record

Type
Traditional
Received
Mar 14, 2025
Review panel
Radiology
Regulation
21 CFR 892.1680

One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.